CA2864655A1 - Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes - Google Patents

Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes Download PDF

Info

Publication number
CA2864655A1
CA2864655A1 CA2864655A CA2864655A CA2864655A1 CA 2864655 A1 CA2864655 A1 CA 2864655A1 CA 2864655 A CA2864655 A CA 2864655A CA 2864655 A CA2864655 A CA 2864655A CA 2864655 A1 CA2864655 A1 CA 2864655A1
Authority
CA
Canada
Prior art keywords
val
leu
ala
hsp60
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2864655A
Other languages
English (en)
French (fr)
Inventor
Irun R. Cohen
Raanan Margalit
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CA2864655A1 publication Critical patent/CA2864655A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2864655A 2012-03-01 2013-02-28 Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes Abandoned CA2864655A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605262P 2012-03-01 2012-03-01
US61/605,262 2012-03-01
PCT/IL2013/050174 WO2013128450A1 (en) 2012-03-01 2013-02-28 Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

Publications (1)

Publication Number Publication Date
CA2864655A1 true CA2864655A1 (en) 2013-09-06

Family

ID=48050870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864655A Abandoned CA2864655A1 (en) 2012-03-01 2013-02-28 Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

Country Status (8)

Country Link
US (1) US20150018271A1 (OSRAM)
EP (1) EP2819692A1 (OSRAM)
JP (1) JP2015508812A (OSRAM)
CN (1) CN104244967A (OSRAM)
AU (1) AU2013227249A1 (OSRAM)
CA (1) CA2864655A1 (OSRAM)
IN (1) IN2014MN01887A (OSRAM)
WO (1) WO2013128450A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4061832A4 (en) * 2019-11-18 2024-05-29 The Methodist Hospital System NANOVACCIN AGAINST HEART FAILURE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5578303A (en) 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
US5780034A (en) 1989-03-14 1998-07-14 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
PT820303E (pt) 1994-12-21 2003-10-31 Yeda Res & Dev Analogos do peptido p277 e composicoes farmaceuticas que os compreendem, para tratamento ou diagnostico de diabetes
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
IL114407A0 (en) 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
WO2003070761A1 (en) 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
EP1718158B1 (en) * 2004-01-28 2014-07-02 Andromeda Bio Tech Ltd. Hsp therapy in conjunction with a low antigenicity diet
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20070128193A1 (en) * 2004-12-22 2007-06-07 O'neil Karyn T GLP-1 agonists, compositions, methods and uses
EP1835933A4 (en) * 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
US20150018271A1 (en) 2015-01-15
WO2013128450A1 (en) 2013-09-06
EP2819692A1 (en) 2015-01-07
IN2014MN01887A (OSRAM) 2015-07-10
JP2015508812A (ja) 2015-03-23
AU2013227249A1 (en) 2014-09-11
CN104244967A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
JP2548056B2 (ja) Ｉ型糖尿病に係る自己免疫疾患の抑制および予防用製剤
US5952301A (en) Compositions and methods for enhancing intestinal function
RU2493868C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
ES2320754T3 (es) Tratamiento de la diabetes.
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
RU2546520C2 (ru) Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
RU2623023C2 (ru) Ликсисенатид и метформин для лечения диабета типа 2
RU2684398C2 (ru) Состав с постоянным соотношением инсулина гларгина/ликсизенатида
JP2006506386A5 (OSRAM)
TWI748945B (zh) 第２型糖尿病病患治療
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
US20230092769A1 (en) Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
US20150018271A1 (en) Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
US20150011471A1 (en) Regeneration of islet beta cells by hsp60 derived peptides
EP3402505B1 (en) Pharmaceutical formulations for the treatment of diabetes
WO2023131619A1 (en) Il-4 derived peptides for use in the treatment of obesity
WO2015170286A2 (en) Modulation of blood glucose levels
US20130090289A1 (en) Method of Treatment of Type 2 Diabetes
US20200054716A1 (en) Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies
WO2021142736A1 (en) Dosing regimen of glp-1

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170228